U.S. health advisers said Thursday that some Americans who have received the modern Covid vaccine should receive a half-dose booster to increase protection against the virus.
A panel of Food and Drug Administration advisers unanimously voted to recommend a booster shot for the elderly, with other health issues, jobs or living conditions that put them at increased risk for COVID-19.
The recommendation is non-binding, but it is an important step in expanding the US booster campaign to millions more Americans. Many people who received their initial Pfizer shots at least six months ago are already receiving boosters after the FDA approved their use last month.
As far as food is concerned, the initial modern vaccination consists of two 100 microgram shots. But Moderna says a 50 microgram shot booster should be enough.
The agency called its experts on Thursday and Friday to review who should receive the booster and when for those who received the Moderna and Johnson & Johnson shots earlier this year.
The FDA will use the recommendations of its advisers to make the final decision on booster for both companies. Next week, a panel from the Centers for Disease Control and Prevention will provide more details on who should get it.
U.S. officials have stressed that the priority is to get shots to the 66 million non-immunized Americans who are eligible for immunizations – who are most at risk because of the additional coronavirus contagious delta across the country. Different types have been burned.
“It’s important to remember that vaccines still provide strong protection against serious consequences,” said Dr. Peter Marks, head of the FDA’s vaccines.
But Marx said it was also clear that the three coronavirus vaccines used in the United States had some protection against mild infections, and urged the advisory panel to consider whether. Evidence supports similar booster recommendations for all of them. It will “at least confuse” the public.
Moderna is seeking FDA clearance for a booster used like Pfizer: for people 65 or older, or for adults with other health issues, jobs or living conditions that make them seriously coronary. Put them at increased risk for the virus – once they have had their last dose for at least six months
The FDA will use the recommendations of its advisers to decide whether to authorize Moderina Booster. If that happens, there is still another hurdle: next week, a panel from the Centers for Disease Control and Prevention will provide more details on who should get it.
The Associated Press Health and Science Department is supported by the Department of Science Education at Howard Hughes Medical Institute. The AP is fully responsible for all content.